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Epstein-Barr Virus Transactivates the Human
Endogenous Retrovirus HERV-K18
that Encodes a Superantigen
(APCs) to autologous T cells. The EBV-infected B cells
strongly and rapidly stimulated T cells, with kinetics
and magnitude similar to a mitogenic response. The
response was initially TCRBV13 specific (within 4–6 hr),
followed by polyclonal activation (after 48 hr). The T cell
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2 Department of Genetics and Microbiology stimulation was MHC class II dependent because it
could be blocked using antibodies against HLA-DR andUniversity of Geneva Medical School
1211 Geneva 4 was not due to a recall antigen response; human umbili-
cal cord blood T cells responded similarly. Finally, theSwitzerland
TCRBV13 specificity was confirmed using a panel of
chimeric murine T cell hybridomas (THys) expressing
human TCRBV genes. We proposed that SAg-mediatedSummary
T cell activation could play a role in the establishment
and/or maintenance of EBV infection (Sutkowski et al.,Superantigens (SAgs) are proteins produced by patho-
genic microbes to elicit potent, antigen-independent 1996), which results in lifelong viral persistence in the
resting memory B cell compartment (Babcock et al.,T cell responses that are believed to enhance the mi-
crobes’ pathogenicity. Here we show that the human 1998). SAg driven T cell stimulation could also play a
role in EBV-associated diseases.lymphotropic herpesvirus Epstein-Barr virus (EBV)
transcriptionally activates the env gene of an endoge- Despite an extensive search, we have been unable
to identify an EBV gene encoding this SAg. Thus, wenous retrovirus, HERV-K18, that possesses SAg activ-
ity. SAg activity was demonstrated by MHC class II hypothesized that EBV may transactivate an endoge-
nous gene that has SAg activity. To this end, we noteddependent preferential activation of TCRVB13 T cells
in response to murine B cells transfected with the that the human endogenous retrovirus HERV-K18 was
recently localized to chromosome 1q21.2-q22 (HasuikeHERV-K18 env gene. This is a unique demonstration
of a pathogen inducing a host-encoded Sag and ac- et al., 1999; Tonjes et al., 1999; Stauffer et al., 2001 [this
issue of Immunity]) in the first intron of CD48, an EBV-counts for the previously described EBV associated
Sag activity. The T cell activation elicited by the Sag transactivated gene (Thorley-Lawson et al., 1982). An
EBV-inducible enhancer had been previously mappedcould play a central role in EBV infection and associ-
ated diseases. to a region 1.58 kb upstream of the CD48 start site
(Klaman and Thorley-Lawson, 1995). It was also shown
that the IDDMK1,222 retrovirus (Conrad et al., 1997) is anIntroduction
allelic variant of HERV-K18 (Hasuike et al., 1999; Tonjes
et al., 1999), designated allele 1 or K18.1 (Stauffer et al.,Superantigens (SAgs) are believed to play a critical role
in the pathogenesis of certain microorganisms through 2001), whose env gene encodes SAg activity (Conrad
et al., 1997). Thus, a host-encoded SAg was localizedtheir ability to stimulate a large fraction of primary T cells
(Marrack and Kappler, 1990). They do this by associating to a region of DNA in the vicinity of an EBV-inducible
enhancer. These findings led us to test whether anywith MHC class II molecules and binding to T cells that
express particular T cell receptor (TCR)  chain variable of the HERV-K18 env alleles possessed TCRBV13 SAg
activity that could be transactivated by EBV.(TCRBV) genes. This distinguishes them from conven-
tional peptide antigens that bind to the groove formed Here, we present evidence that this is indeed the case.
We found that both HERV-K18.1 and K18.2 alleles spe-by the  and  chains of the TCR and thus activate only
a small population of specific T cells due to the genomic cifically stimulated TCRBV13 and BV9 THys, but not
other THys, and stimulated strong proliferation of pri-and somatic diversity of the TCR genes. It is believed
that the T cell stimulation elicited by the SAg in some way mary T cells. We show that EBV infection leads to tran-
scriptional activation of HERV-K18 env and that the EBV-benefits the pathogen because SAgs are evolutionarily
conserved within a species. There are two groups of associated SAg activity can be blocked with an antise-
rum specific for HERV-K18 Env. The implications ofmicroorganisms that are known to have SAgs: bacterial
and viral. Whereas a large number of bacterial SAgs these findings are discussed in light of what is known
about EBV biology and its transforming qualities.have been well characterized structurally and function-
ally, only three families of viruses have been associated
with SAg activity to date: retroviruses, rhabdoviruses, Results
and herpesviruses (Huber et al., 1996).
We have reported previously that EBV-infected B cells HERV-K18 Env Alleles and EBV-Infected B LCL
express a TCRBV13-specific SAg (Sutkowski et al., Have Identical TCRBV Specificity, which Is Inhibited
1996). The activity was characterized using an in vitro by HERV-K18 Env Antiserum and MHC
model system in which EBV-transformed B lymphoblas- Class II Antibodies
toid cell lines (LCLs) served as antigen-presenting cells The HERV-K18 env alleles 1 and 2, K18.1 and K18.2,
differ at several positions: The K18.1 Env has a stop
codon at aa 153, whereas the K18.2 Env is a full-length3 Correspondence: brigitte.huber@tufts.edu
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553 aa protein (Stauffer et al., 2001). These are the two both EBV-latent and lytic antigens but does not contain
most common K18 env alleles, found in up to 90% of the HERV-K18 provirus (Barbulescu et al., 1999). Consis-
chromosomes tested in the Caucasion population tent with the idea that HERV-K18, not an EBV encoded
(Stauffer et al., 2001). Because the K18.1 allele had been protein, is the SAg, B95-8 cells did not stimulate the
previously characterized (Conrad et al., 1997), we tested TCRBV13 THys.
whether the full-length env of K18.2 could stimulate T At APC/responder ratios of 5:1, the K18 Env alleles
cells. We cloned the entire HERV-K18.2 provirus using the and B95-8 infected BL41 and LCL also stimulated the
chromosome 1 insertion sequences previously reported hTCRBV9 THy (Choi et al., 1990, 1991), suggesting an
(Ono et al., 1986; Tonjes et al., 1999) as PCR primers. additional TCR specificity for the SAg. These data show
After sequencing, the env gene was subcloned into the that both K18 env alleles have the same TCRBV specific-
bicistronic expression vector pCDLI (Stauffer et al., ity as the EBV-associated SAg. In this assay the trun-
2001), with the marker EYFP (enhanced yellow fluores- cated K18.1 Env reproducibly stimulated the TCRBV13
cent protein) in the second cistron. Murine A20 B lym- THys to make more IL-2 than the K18.2 Env protein.
phoma cells were chosen for transfection experiments This difference likely reflects lower-level expression of
because the mouse genome does not have any HERV- the full-length K18.2 env due to its toxicity in the A20
related proviruses (Barbulescu et al., 1999). Stable cells, which was not observed with the truncated K18.1
clones expressing different levels of EYFP were selected env allele.
by flow cytometry and tested for TCRBV13 T cell activa- To test whether the SAg activity was due to K18 Env,
tion. We have previously described a system to assay we employed a rabbit antiserum raised against the K18
for EBV-associated SAg activity (Sutkowski et al., 1996) Env peptide 116-130. This antigenic peptide was se-
based on the stimulation of murine THys with EBV- lected using the hydrophilicity index of Kyte and Doolit-
infected B cell lines acting as APCs. These THys bear tle (1982). The K18 Env antiserum specifically blocked
chimeric TCRs composed of a human (h) TCRBV gene immune recognition of the K18.1 and K18.2 env alleles
product with murine chain and CD3 proteins. As shown by the TCRBV13S1 and TCRBV13S2 THys in a dose-
in Figure 1A, all of the K18.2 env transfectants (A20/ dependent manner, whereas the preimmune serum had
K18.2) stimulated the hTCRBV13 THy, but not the no effect (Figure 2A). We then used this antiserum to
hTCRBV8 THy, whereas both THys were equally acti- prove that the TCRBV13 activation by EBV infected cells
vated by CD3 crosslinking. The magnitude of the re- was mediated by K18 Env. As shown in Figure 2B, the
sponse was similar to that elicited by a LCL made from Env antiserum blocked stimulation of these THys by
B cells from a K18.2 donor transformed by the B95-8 EBV-transformed LCL and EBV-infected BL41, whereas
strain of EBV, whereas untransfected A20 cells gave no no blocking was observed with the preimmune serum.
response. Similar results were obtained by transfecting The blocking effect was not due to toxicity by the Env
K18.2 env into the human EBV B cell lymphoma BJAB antiserum because it had no effect on an anti-CD3 re-
(data not shown). Pretreatment of all APC lines with the sponse. These data provide evidence that the TCRBV13-
phorbol ester PMA was necessary for stimulation of the specific SAg activity associated with EBV is due to the
THys, as was previously shown for the EBV-associated env gene product of the endogenous HERV-K18 pro-
SAg activity (Sutkowski et al., 1996). In addition, HERV virus.
K18.2 Env appeared to be toxic to the B cells, because We have previously shown that the EBV-associated
EYFPhi cells rapidly died off, selecting for EYFPlo or nega- SAg activation of peripheral blood T cells is dependent
tive cells. These data indicate that the K18.2 env allele upon MHC class II presentation because it could be
has SAg activity for TCRBV13, just like the EBV-associ- blocked by antibody specific for HLA.DR (Sutkowski et
ated SAg (Sutkowski et al., 1996). al., 1996). To determine whether the TCRBV13 activation
To test whether the K18.2 env transfectants stimu- by A20/K18.1 Env was MHC class II dependent, we pre-
lated other T cell subsets, we used a panel of murine
incubated the A20/K18.1 Env cells with mAb specific
THys expressing different hTCRBV genes. In addition,
for MHC class I, H-2Dd; MHC class II, I-Ab/d or I-Ek/d/p/r;
we examined the response to the truncated K18.1 env
or as a negative control, HLA.DR. The A20 cell line wasallele transfected into A20 cells. The results, depicted in
derived from BALB/c mice of the H-2d haplotype. As aFigure 1B, show the comparison between the response
specificity control, B95-8 LCL were preincubated with theobtained with a B95-8 LCL and the transfected A20
same antibodies. As can be seen in Figure 2C, K18.1cells. The LCL and both K18 env alleles stimulated the
Env presentation in A20 cells was blocked by the anti-I-EhTCRBV13S1 and hTCRBV13S2 THys (Choi et al., 1990,
antibody but not by antibodies specific for HLA.DR, H2-D,1991), but not the hTCRBV2, 3, 8, or 17 THys (Blank et
or I-A. The anti-I-E antibody did not inhibit SAg presenta-al., 1993; Sutkowski et al., 1996), whereas A20 trans-
tion by the B95-8 LCL, whereas, as expected, the anti-fected with pCDLI vector alone did not stimulate any of
HLA.DR antibody did block. Thus, the response is MHCthe hybridomas. EBV induction of the stimulatory activity
class II dependent, and it appears that in mouse, APCwas demonstrated by comparing the APC function of
K18 Env is primarily presented by I-E molecules, thethe EBV Burkitt’s lymphoma BL41 and its counterpart,
functional homolog of HLA.DR.BL41 infected with B95-8 EBV (Calender et al., 1987).
At high APC ratios, uninfected BL41 weakly stimulated
EBV Transcriptionally Activates HERV-K18 envthe very sensitive hTCRBV13S1 THy, most likely due to
in B LCL and Burkitt’s Lymphomathe low level of endogenous K18 env expression in these
with Functional Consequencetumor cells (see Figure 3); however, infection with B95-8
To test whether EBV could upregulate HERV-K18 envEBV greatly enhanced stimulation. The marmoset cell
line B95-8, from which the virus was derived, expresses expression, as it does CD48 (Thorley-Lawson et al.,
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Figure 1. HERV-K18 Env and the EBV-Associated SAg Preferentially Activate hTCRBV13 and hTCRBV9 THys
(A) Untransfected A20 cells, or five individual clones of A20 stably transfected with HERV-K18.2 env, were pretreated with PMA and then
resuspended with an equal number of hTCRBV13S1 (closed bars) or hTCRBV8 THy (open bars). After a 48 hr incubation, IL-2 production was
measured in the cell supernatants by ELISA. The response was compared with that obtained with PMA-treated B95-8 transformed B LCL
from the HERV-K18.2 env donor or with anti-CD3 crosslinkage.
(B) A20 transfected with HERV-K18 env alleles 1, 2, or vector only (A20/K18.1 env, A20/K18.2 env, A20/pCDLI, resp.); B95-8 transformed LCL,
BL41, and BL41/B95-8 infected cells were pretreated with PMA/mitomycin C and resuspended with the indicated hTCRBV THy at APC/
responder ratio of 5:1 (closed bars) or 1:1 (open bars). The results are expressed as percentage maximal IL-2 production, based on the
stimulation of each THy by anti-CD3 crosslinkage because the THy differ significantly. Maximal IL-2 production (pg/ml) for this assay: TCRBV2
389.1  108.2; TCRBV3  255.7  16.3; TCRBV8  497.2  11.7; TCRBV9  34.1  14.7; TCRBV13S1  141.2  13.5; TCRBV13S2  19.8 
9.9; and TCRBV17S1  58.05  36.9. Results are representative of at least three independent assays.
1982), we used an RNase protection assay designed to Figure 3A, the protected env transcripts, consisting of
a 300 bp band, are readily detected in a B95-8 EBVdetect all of the K18 env alleles but not other HERV-K
env transcripts (Stauffer et al., 2001). As can be seen in transformed LCL and are also upregulated when EBV
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BL41 cells are converted to EBV by infection with B95-8 To determine whether this transcriptional activation is
functionally relevant, primary B cells were LPS activatedvirus (Calender et al., 1987). The human TATA binding
protein (hTBP) was used as a loading control. Interest- and compared with their B95-8-transformed counter-
part for activation of the TCRBV13S1 THy. LPS wasingly, treatment of the APC with PMA had no effect on
K18 env transcription, as could be seen by measuring added to keep the primary B cells alive throughout the
48 hr hybridoma assay. Again, EBV LCL were used inthe densitometry ratios of the level of K18 env to hTBP
at 2, 8, or 16 hr following PMA treatment. Thus, the PMA place of freshly EBV-infected B cells because the assay
requires 48 hr to perform and because the phenotypeenhancement of SAg activity does not work at the level
of K18 env transcription. It is likely that PMA affects the of B cells 24–32 hr after EBV infection is identical to that
of EBV LCL (Alfieri et al., 1991). As can be seen in Figuremode of SAg presentation required for efficient T cell
activation in vitro, as has been seen in other systems 3C, the B95-8 LCL from each individual elicited higher
IL-2 production than the LPS activated B cells, even(Pesando et al., 1986; Yasukawa et al., 1988; Barois et
al., 1997; Anderson et al., 1999). These data show that at lower APC/responder ratios, indicating a functional
consequence to the upregulation of HERV-K18 env tran-EBV directly transactivates K18 env expression in EBV-
infected cell lines. EBV BL41 cells express maximal scripts by EBV. On the other hand, B cells cultured in
the presence of soluble CD40L did not lead to functionallevels of CD48 transcripts, which are not further en-
hanced by infection with B95-8 EBV (Klaman and Thor- SAg expression (Stauffer et al., 2001).
ley-Lawson, 1995). Thus, our results indicate that merely
opening the chromosomal region of CD48 for transcrip- HERV-K18 Env Alleles and Autologous EBV LCL
Strongly and Rapidly Activate Primary T Cells,tion leads to minimal expression of HERV-K18 env,
whereas EBV infection superinduces this transcript ap- and the Stimulation Is Blocked by HERV-K18
Env Antiserumproximately 10-fold (Figure 3A). To confirm these results,
we developed a semiquantitative RT-PCR designed to To confirm the stimulatory activity of K18 Env on primary
T cells, we measured proliferation of peripheral blooddetect HERV-K18 read-through transcripts specific for
chromosome 1 insertion sequences adjacent to the pro- T cells induced by A20 cells that were transfected with
K18.1 env. In all cases, APC lines were pretreated forvirus 3 LTR. Up to 15% of all retroviral transcripts had
been shown to be read-through transcripts containing 16 hr with PMA, washed, and treated with mitomycin
C to inhibit proliferation. APCs were then extensivelychromosomal sequences immediately downstream of
the insertion site of the provirus (Herman and Coffin, washed and cocultured with peripheral blood mononu-
clear cells at APC/responder ratios of 1:1, 1:3, or 1:10.1986). RNA was isolated from primary B cells and en-
riched by negative selection from peripheral blood T cell proliferation was assessed 48 hr after coculture,
as measured by uptake of [3H]thymidine. As can be seenmononuclear cells from three healthy adult volunteers
and also from B95-8 LCL derived from these donors. We in Figure 4A, PMA/mitomycin C pretreated A20/ K18.1
Env vigorously and rapidly stimulated T cells, while pre-compared HERV-K18 env transcription in the purified B
cells directly with that in LCL because the phenotype treated A20/pCDLI conferred only minimal activity. The
response was comparable in both magnitude and kinet-of infected B cells 24–32 hr after EBV infection is indistin-
guishable from that of EBV LCL (Alfieri et al., 1991). ics to that elicited with autologous B95-8 transformed
LCL, as was previously shown for the EBV-associatedRNA was reverse transcribed either by random or gene-
specific priming using an oligo directed against the chro- SAg activity (Sutkowski et al., 1996) or the mitogen PHA.
Control wells containing APC only did not incorporatemosome 1 insertion sequence located 293 bp down-
stream of the 3LTR. PCR primers were designed to [3H]thymidine. It should be noted that only T cell prolifer-
ation is measured in this assay, not activation of particu-amplify a 1161 bp region of cDNA originating in the
env gene and progressing through the 3LTR 122 bp lar TCRBV subsets. Earlier studies had indicated that the
EBV-associated SAg elicits a polyclonal T cell activationdownstream into the adjacent chromosome 1 sequence.
As an endogenous standard, primers specific for 18s (Sutkowski et al., 1996), and we have similar findings
for A20/ K18.1 Env (data not shown).rRNA were included in the reaction. The results are pre-
sented in Figure 3B. For each individual, a relative induc- To demonstrate that EBV induction of K18 env was
driving this polyclonal proliferation, we again performedtion of HERV-K18 transcripts of approximately 2- to
4-fold after B95-8 transformation was seen, confirming antibody-blocking experiments, using the rabbit antise-
rum raised against the K18 Env peptide (Figure 4B).that EBV transcriptionally activates HERV-K18 env in
primary B cells. The antiserum blocked peripheral blood T cells from
Figure 2. Anti-HERV K18 Env Antiserum and MHC Class II Antibodies Block Activation of THy by K18 Env Transfectants and the EBV-
Associated SAg
(A) PMA/mitomycin-C-pretreated A20/K18.1 env, A20/K18.2 env were incubated with Env antiserum, diluted 1:100 or 1:200, or with preimmune
serum (1:100) for 30 min prior to addition of hTCRBV13S1 THy (closed bars) or hTCRBV13S2 THy (open bars) at an APC/responder ratio of
2:1. IL-2 production was measured 24 hr later. The response was compared with A20/pCDLI (negative control).
(B) PMA/mitomycin-C-pretreated B95-8 marmoset cells, B95-8 LCL, BL41, or BL41/B95-8 were incubated with the hTCRBV13S1 THy (closed
bars) or hTCRBV13S2 THy (open bars) as described above. B95-8 LCL and BL41/B95-8 were also pretreated with Env antiserum, diluted
1:100 or 1:200, or with preimmune serum at 1:100. IL-2 production was measured 24 hr later. The responses were compared with that elicited
by anti-CD3 crosslinkage. As toxicity control, the Env antiserum was also added to anti-CD3 wells.
(C) PMA-pretreated A20, A20/K18.1 env, or B95-8 LCL were preincubated with antibodies specific for HLA.DR, H-2Dd, I-Ad, or I-Ek/d and then
added to hTCRBV13S1 at an APC/responder ratio of 1:1. IL-2 production was measured 24 hr later.
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Figure 3. B95-8 EBV Transcriptionally Acti-
vated HERV-K18 env Expression in B Cells with
Functional Significance for T Cell Activation
(A) Total RNA from B95-8 transformed LCL,
BL41, or BL41/B95-8 infected cells, treated
for 0, 2, 8, or 16 hr with PMA, were incubated
with riboprobes specific for HERV-K18 env
alleles and hTBP (loading control), and then
digested with RNases, and run on a 6% poly-
acrylamide gel. Protected fragments for
HERV-K18 env were detected at 300 b, and
the loading control hTBP as a doublet at
161 b. As controls, RNA from A20 and A20
transfected with K18.1 env were included.
(The A20/K18.1 env construct has an addi-
tional 30 b of Bluescript vector sequence that
is protected by the riboprobe, accounting for
the difference in size between positive control
and the 300 b K18 env band.) Densitometry
value ratios for the K18 env: hTBP doublet
are indicated below each lane.
(B) Relative quantitative RT-PCR was per-
formed using RNA derived from purified B
cells from three different donors (1–3) and
B95-8 transformed B LCL from the same
three donors. Primers were designed to de-
tect a 1161 bp HERV K18 read-through tran-
script that traverses the env gene, 3 LTR,
and adjacent chromosome 1 sequences lo-
cated up to 122 bp downstream of the 3
LTR. 25 PCR cycles were determined to yield
product within the linear range. Because the
read-through transcripts were extremely rare,
PCR was performed in the presence of [32P]
-dCTP. As endogenous standard, primers
specific for an 18s rRNA 489 bp product were
used in each reaction; and as negative con-
trols, H2O only and no RT reactions were si-
multaneously performed. PCR products were
separated on a 6% denaturing acrylamide gel
and quantified by Phosphorimaging. The ra-
tios of HERV K18:18s rRNA are printed below
each lane, and the fold induction of HERV
K18 transcripts after B95-8 transformation is
depicted for each individual (B95-8:B).
(C) Purified primary B cells from three individ-
uals were treated with LPS (open bars) and
compared with B95-8-transformed B LCL de-
rived from the same blood donors (closed
bars). Both LPS B cells and B95-8 LCL were
pretreated with PMA, washed, and incubated
with the hTCRBV13S1 THy at various APC/
responder ratios using 2 104 THy per qua-
druplicate well. IL-2 production was mea-
sured 48 hr later.
responding to A20/K18.1 Env in a dose-dependent man- Figure 2B, showing that B95-8 marmoset cells do not
activate TCRBV13 THys. These experiments indicatener, whereas preimmune serum was not inhibitory. On
the other hand, the response to the mitogen PHA was that the polyclonal T cell proliferation elicited by the
EBV LCL is a direct consequence of HERV-K18 envunaffected, indicating that the antiserum was not toxic
to the responding T cells. expression. Whether the polyclonal activation is a down-
stream event of the TCRBV13 specific response or aThe Env antiserum also completely blocked the strong
T cell proliferative response of an EBV sero-negative separate activity of the K18 env product is not clear.
donor to autologous LCL derived from in vitro transfor-
mation of B cells with B95-8 EBV, excluding the possibil- Discussion
ity that the elicited T cell proliferation was due to a
potent recall response to EBV. Moreover, no response We have shown that EBV infection of B cells leads to
transactivation of HERV-K18 env alleles, which expressby this EBV donor was seen to the EBV marmoset
cell line B95-8, analogous to the results depicted in a TCRBV13 specific SAg activity previously identified
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a T cell dependent event (Gray et al., 1997; Liu and Arpin,
1997; Liu and Banchereau, 1997), the SAg-elicited T cell
help would fulfill this requirement. This is particularly
tantalizing because it has been observed that marmosets,
New World primates that do not contain HERV-K18 in
their genome (Barbulescu et al., 1999), are unable to
establish long-term, persistent EBV infection even when
efficiently infected with EBV in vivo (D.A.T.-L., unpub-
lished data).
Other herpesviruses have been associated with SAg-
like activities. Herpesvirus saimiri Orf-14 was identified as
a viral protein having homology to the MMTV SAg, Mls-1
(Yao et al., 1996). Orf-14 was reported to activate T cells
polyclonally (Yao et al., 1996), similar to a mitogen. Inter-
estingly, deletion of orf-14 from the saimiri genome re-
sulted in a virus with reduced ability to transform primate
T cells in vivo (Duboise et al., 1998). Infection with cyto-
megalovirus was associated with a TCRBV12 T cell re-
sponse; however, no gene has been identified encoding
this activity (Dobrescu et al., 1995). It is possible that this
herpesvirus transactivates another HERV gene that has
TCRBV12-restricted SAg activity. The murine 	-herpesvi-
rus is associated with a mouse TCRBV4-restricted T cell
response but does not entail the traditional characteris-
tics of a SAg (Tripp et al., 1997; Coppola et al., 1999),
and, again, no gene has been identified that encodes
this T cell stimulatory activity. These observations imply
that herpesviruses may have evolved different mecha-
nisms enabling them to elicit T cell help in the infected
host. This may be analogous to the various mechanisms
used by these viruses to avoid recognition by cytotoxic
T cells, such as downregulating MHC class I expression
(Ploegh, 1998). In the scenario of EBV-transactivating
HERV-K18 expression, it will be interesting to study the
interplay of biological activity that has allowed the evolu-
tionary retention of an endogenous retrovirus that po-
Figure 4. The EBV-Associated SAg, HERV-K18 Env, Strongly Stimu-
tentially benefits a persistent herpesvirus.lated Peripheral Blood T Cells with Rapid Kinetics
In vitro detection of the HERV-K18 SAg activity required(A) PMA/mitomycin-C-treated A20/K18.1 env or A20/pCDLI and au-
a highly defined system whereby murine transfectantstologous B95-8 transformed LCL were used as APC in 48 hr T cell
presented the K18 env gene product to hTCRBV-spe-proliferation assays, as measured by the incorporation of [3H]thymi-
cific THys. The chimeric human/mouse TCR of the THysdine. APC/responder ratios of 1:1 (closed bars), 1:3 (gray bars), and
1:10 (open bars) show that T cell proliferation is dependent upon revealed the preference for TCRBV 13S1, 13S2, and 9
antigen dose. The response was compared with the mitogen PHA, gene products. In primary cells, the EBV-associated T cell
and APC only were shown for comparison. response is also TCRBV13 restricted initially; it then
(B) Preincubation with HERV-K18 Env antiserum at 1:100 and 1:200
rapidly becomes polyclonal (Sutkowski et al., 1996). Wedilutions blocked 48 hr T cell proliferation to PMA/mitomycin-
have shown here that K18 Env alone induces this poly-C-treated A20/K18.1 Env, whereas preimmune serum, added at
clonal response in peripheral blood T cells when pre-1:100, was noninhibitory. In addition, T cell proliferation to autolo-
sented by transfected mouse APC (Figure 4). We sawgous B95-8 transformed LCL from an EBV-seronegative donor was
blocked by the Env antiserum, but not by the preimmune serum, no evidence of TCRBV-specific expansions in peripheral
whereas the Env antiserum had no effect on T cell proliferation due blood T cells, despite the massive T cell proliferation
to PHA. The B95-8 marmoset cell line, which produces high titer (data not shown). It is possible that the polyclonal activa-
EBV, was not stimulatory to the EBV seronegative donor T cells.
tion could be a direct downstream consequence of the
early TCRBV13-specific effect. Alternatively, it could be
a separate property of the env gene product that masks
as an EBV-associated SAg (Sutkowski et al., 1996). This the TCRBV13-specific effect at later times. Similar poly-
represents a demonstration of a microbial pathogen, clonal effects have been seen with bacterial SAgs in
EBV, inducing an endogenous SAg in humans. SAgs toxin titration experiments (Fleischer et al., 1996);
are believed to provide an advantage for the pathogen, namely, above a particular threshold, TCRBV restriction
facilitating its transmission in the host (Huber et al., 1996; was lost, and all T cells were activated. In our experimental
Acha-Orbea et al., 1999). Therefore, it is conceivable that system, it was difficult to control the amount of HERV-
EBV makes use of the SAg-induced T cell stimulatory K18 Env protein that was presented to T cells. We accom-
activity to establish persistent infection in vivo, ulti- plished this by varying the APC/responder ratios; how-
mately residing in the memory B cell pool (Babcock et ever, this is very different from adding known amounts
of soluble protein, as is done with the bacterial toxins.al., 1999). Because B cell memory formation is clearly
Immunity
586
PMA treatment of the APCs was required to detect panded in IM and account for much of the lymphocytosis
SAg activity in all transfected clones and EBV lines. (Callan et al., 1998; Blake et al., 2000), murine studies
Clues to the mechanism of PMA enhancement are sug- have demonstrated that administration of a bacterial
gested by the MMTV system, which employs the best- SAg to virally infected animals resulted in an augmented
analyzed viral SAg, Mls-1. We obtained comparable and protracted viral CTL response (Coppola and Black-
findings with Mls-1 transfectants, where preincubation man, 1997). Hence, an EBV-induced SAg activity may
of the APCs with IL-4 yielded a more efficient T cell not only be critical at the early stages of EBV infection
stimulation read-out, although there was no increase in facilitating transmission of the virus, but could also play
mls-1 mRNA levels (Beutner et al., 1992a, 1992b). In- a role in enhancing the EBV-specific CTL response. We
stead, the IL-4 was likely boosting the level of MHC are currently testing these models in vitro and in vivo in
class II transcription (Roehm et al., 1984; Finn et al., the SCID system.
1991), allowing more efficient presentation of Mls-1 on
newly synthesized class II molecules. PMA, like IL-4,
Experimental Proceduresinitiates MHC class II expression (Pesando et al., 1986;
Yasukawa et al., 1988). Although Mls-1 has been studied Cell Lines, Antibodies, and DNA Constructs
for years, it is still not clear how it associates with MHC All cell lines were grown in RPMI supplemented with 10% FCS,
class II nor in what cellular compartment (Hsu et al., 2001). glutamine, HEPES, Na pyruvate, and -mercaptoethanol (all tissue
culture reagents from GIBCO Life Technologies). A20 is a murine BIt is known that Mls-1 presentation to T cells requires both
cell lymphoma (BALB/c background). Burkitt’s lymphoma lines BL-41glycosylation and proteolytic processing by arginine-
and BL-41/B95-8 (Calender et al., 1987) were a gift from Gilbertspecific, and possibly other, proteases (Mix and Wins-
Lenoir. PBMC were obtained from the whole blood of healthy adult
low, 1996; Denis et al., 2000). We show here that PMA volunteers by density gradient separation on Ficoll-Paque Plus
treatment of the APCs also does not affect the level of (Pharmacia). B95-8 virus was derived by 0.4-
m filtering 5 day cell
HERV-K18 env transcription (Figure 3). By analogy to supernatants of confluent B95-8 marmoset cells (Miller and Lipman,
1973). Viral supernatants were either used immediately or frozenthe MMTV system, PMA treatment may facilitate presen-
in aliquots at 80C. B95-8 LCL were obtained by incubating 107tation of the EBV SAg by affecting posttranslational
freshly isolated PBMC with 1 ml of B95-8 supernatant that wasmodification or trafficking of the SAg. For example, it
diluted 1:1 in media for 2 hr at 37C. Cells were then diluted in 10has been recently shown that protein kinase C phos- ml media with the addition of cyclosporin A (1 
g/ml) and placed
phorylation directly affects MHC class II trafficking and at 37C for 2–3 weeks. The medium was changed during this time
antigen presentation pathways in APCs (Barois et al., every 5 days. Once the growing LCL became confluent, cyclosporin
A was removed. All THy lines were described previously (Sutkowski1997; Anderson et al., 1999).
et al., 1996) and were kindly donated by Philippa Marrack or Rafick-Mls expression in B cells from mice naturally infected
Pierre Sekaly. Briefly, the TCRBV2 cell line was TAL 8.1.9 (Blank etwith MMTV is even lower than that derived from an
al., 1993); TCRBV3 THy was 58--/HAI-7/; TCRBV8 THy wasendogenous SAg, requiring a highly sensitive PCR reac-
YL8#24; TCRBV9 THy was DS3-A; TCRBV13S1 THy was hV13.1-1;
tion coupled with Southern blotting for detection (Beut- TCRBV13S2 THy was hV13.2-1 (Choi et al., 1990, 1991); and TCR-
ner et al., 1994). This level is sufficient to facilitate the BV17 THy was YL17.1#5. THy lines were maintained by occasional
transmission of the infectious virus without the notice- sorting for CD4 and CD3 bright cells (antibodies: FITC-L3T4 and
PE-145 2C11; Pharmingen), using a MoFlo cytometer (Cytomation,able disturbance to the immune system associated with
Fort Collins, CO). Sorted THy were expanded, and aliquots werea strong superantigen response. In fact, no obvious T cell
frozen as early as possible to minimize the spontaneous loss ofactivation in naturally MMTV-infected animals is ob-
CD3 and CD4 during cell division, which leads to reduced IL-2 pro-served, despite the complete dependence on the super-
duction.
antigen stimulation pathway for transmission of the virus HERV K18.2 env was cloned by two-step PCR using genomic
from the gut, the site of primary infection, to the mam- DNA obtained from LCL of different sources. First-step PCR primers
mary tissue. It is likely that EBV-induced HERV-K18 env were specific for the chromosome 1 insertion sequences flanking
the HERV-K18 provirus (Ono et al., 1986; Tonjes et al., 1999). TheSAg activity is also minimal in vivo, sufficient for the
sense primer was 5TACAACATAAGCGGAATCTGAGACTG3, andEBV-infected B cells to receive T cell help without overt
the antisense primer was 5CCCAAACCTTTAAATATTGTCTCATG3.stimulation of the immune system. This scenario fits
The entire provirus was amplified using Expand Long Template PCRvery well with the fact that EBV persists in humans system (Boehringer Mannheim) according to manufacturer’s proto-
throughout our lifetime, causing problems only when col. The second-step PCR used as a template the amplification
the immune system is suppressed. product from step 1, diluted 1:100. Primers were specific for the
Finally, EBV is a highly oncogenic virus, and there is full-length env gene and included SpeI and NotI restriction enzyme
sites for subcloning into the pCDLI bicistronic expression vectorgood evidence that activated T-helper cells contribute
(Stauffer et al., 2001), which has the SR promoter driving expres-to viral pathogenesis. Extensive T cell infiltrates are
sion and the EYFP marker gene encoded in the second cistron. Thecharacteristic of the EBV-associated tumors, Hodgkin’s
sense primer was 5ATACTAGTGAGATGGTAACACCAGTCACAT
lymphoma and naso-pharyngeal carcinoma, as well as GG3, and the antisense primer was 5AAGCGGCCGCTCATGGCCC
transplant-associated lymphomas (PTLD). SCID mice GTTCTCGATGTCACT3. PCR was performed using the Expand High
reconstituted with peripheral blood mononuclear cells Fidelity PCR system (Boehringer Mannheim). PCR products were
(PBMC) from EBV donors develop EBV lymphomas, sequenced after subcloning into the pCDLI expression vector. The
subcloning of HERV K18.1 env DNA into pCDLI was previously de-providing a model for PTLD (Mosier et al., 1988). In this
scribed (Stauffer et al., 2001); pCDLI/I550 transfectants were usedsystem, it was shown that human CD4 T cells greatly
for THy assays, and IDDM465 was used for RNase protectionincrease the development of EBV B cell lymphomas
assays. These constructs differ by inclusion of 550 or 465 nucleo-
(Veronese et al., 1992; Veronesi et al., 1994). Further- tides of K18.1 env. pCDLI/K18.1 (15 
g) or K18.2 env (15 
g), or 15
more, massive lymphocytosis is characteristic of acute 
g pCDLI DNA and 0.5 
g of a hygromycin-carrying plasmid, DZ17,
infectious mononucleosis (IM). Although it has been re- were then cotransfected by electroporation into 2  107 A20 cells
in 0.4 ml of Optimem (GIBCO), using a 0.4 cm cuvette, at 960 
Fported that viral-specific CTL clones are greatly ex-
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and 300 V. Cells were resuspended in 20 ml media overnight and each donor was85% CD20, as assessed by flow cytometry using
FITC-labeled anti-CD20 (BD Pharmingen, San Diego, CA). B95-8were then single-cell subcloned in selective media containing hygro-
mycin (0.5 mg/ml). Two weeks later, individual clones were assayed LCL, previously transformed from the same blood donors, and 24
hr LPS-treated B cells were treated with PMA (10 ng/ml), and cellsfor EYFP expression by flow cytometry using a FACSCalibur. Be-
cause K18.2 env transfectants rapidly lost Env expression, likely were incubated overnight and then washed extensively and resus-
pended with TCRBV13S1 THy at various APC/responder ratios usingdue to toxicity, these cells were not maintained in vitro; instead,
aliquots were frozen as quickly as possible after expansion. K18.1 2  104 THy per well. Plates were frozen after 48 hr, and thawed
supernatants were tested for mIL-2 by ELISA as described above.env transfectants were much more stable.
The anti-HERV-K18 antiserum was obtained by immunizing rabbits
with a HERV-K18 Env peptide consisting of amino acids 116–130, RNase Protection Assay and Semi-Quantitative PCR
CPKEIPKGSKNTEVL, conjugated to KLH (Sigma-Genosys). Rabbits A total of 2  108 BL41, BL41/B95-8, or B95-8 LCL were treated for
were immunized on day 0, 14, 28, 42, 56, and 70. Final bleeds were 0, 2, 8, or 16 hr with PMA (10 ng/ml), and total RNA was prepared
performed within 2 weeks of the last boost. The antibody titer, as with Trizol (Gibco BRL). The RNase protection assay was performed
reported by the manufacturer’s peptide-based ELISA, was as previously described (Staufer et al., 2001) but with 100 
g total
1:100,000. The following antibodies were used in the MHC class RNA/lane. As controls, 100 
g RNA from untransfected A20 cells
II blocking studies: purified anti-HLA.DR, D1-12 (IgG2a) (a gift from and 20 
g RNA from A20 transfected with HERV-K18.1 env
R.-P. Sekaly); anti-I-Ek/d/p/r, IE-D6 (IgG2a) (American Research Prod- (IDDM465) were loaded on the gel. Densitometry values were ob-
ucts, Belmont, MA); anti-I-Ab/d, IA-C6 (IgM) (American Research tained by scanning the autoradiograph with a Biorad Gel Doc 1000,
Products); and anti-H-2Dd/u/p, KD-B4 (IgM) (American Research using the Molecular Analyst program. The ratio of K18 env:hTBP
Products). All antibodies were low endotoxin, sodium azide free, (human TATA binding protein) was determined.
and in PBS. Total RNA was prepared from purified B cells derived using Trizol
from three healthy adult donors (see above for B cell enrichment)
or from B95-8 LCL transformed from the same blood donors. RNAT Hybridoma Assays and IL-2 ELISA
was DNase I treated (Roche) according the manufacturer’s protocolEBV cell lines and stable A20 transfectants expressing HERV-K18.1
and then phenol/chloroform treated to remove the enzyme. cDNAor K18.2 env, growing in log phase, were treated overnight with
was prepared from 1 
g RNA for each sample in 20 
l reactions,PMA (10 ng/ml, Calbiochem) at 37C. Cells were washed once and
using Superscript II reverse transcriptase (Gibco BRL), either bythen treated with mitomycin C (0.1 mg/ml PBS, 107 cells/ml; Sigma)
random priming or with a gene-specific primer, according to thefor 1 hr at 37C and washed extensively in PBS (4, 50 ml). Frozen
manufacturer’s protocol. In all cases, a no-RT control was simulta-aliquots of CD3hi/CD4hi THys were thawed no more than 1–2 days
neously performed. The RT primer was 5 GTGGCAAATTCACTTGGprior to assay to minimize spontaneous loss of CD3. Cells were
CTGA 3. This primer is specific for the chromosome 1q23.1-q24.1counted and resuspended with THy in 96-well, round-bottom plates,
(Accession NT_003229) sequence located 293 bp downstream of thewith 105 or 2  104 APC and 2  104 THy/well in quadruplicates.
HERV-K18 3LTR. Both random priming and gene-specific primingAfter 24–48 hr at 37C, the plates were frozen at 80C to lyse the
yielded similar PCR results (data not shown). The PCR sense primercells, and thawed supernatants were tested for the presence of
was 5 TCCGAAGAGACAGTGACAT 3, which is directed against amIL-2 by ELISA (see below). As positive control, the THys were
HERV K18 env-specific sequence; the PCR antisense primer wascrosslinked with plate-bound anti-CD3. Wells were coated with pro-
5 CTGGCTATGTAAGT 3, which is directed against a chromosometein A (100 
g/ml PBS; ICN Biomedicals) for 2 hr at 37C and then
1q23.1-q24.1 sequence located 122 bp downstream of the 3 viralwith anti-CD3 (145 2C11 culture supernatant diluted 1:150 in PBS)
LTR. The 50 
l PCR reaction consisted of Platinum Taq PCR Su-for 2 hr at 37C. Wells were washed three times with PBS before
permix (GIBCO), 1 
M (final) of each primer, and 0.5 
l of [32P]-addition of THy. IL-2 production for each THy was expressed either
dCTP (10 
Ci/
l) and 2 
l of cDNA (1/10 volume). As an endogenousin pg/ml or as percentage maximal based on the response to anti-
standard, primers against 18s rRNA were included in the reactionCD3 crosslinking.
from the Ambion Gene Specific Relative RT-PCR kit (Ambion Inc.,The murine IL-2 ELISA was performed using as capture antibody
Austin, TX). Because the HERV-K18 read-through transcripts werepurified anti-mouse IL-2 (2 
g/ml, diluted in 0.1 M Na2HPO4 [pH 9.0];
expected to be extremely rare compared with the 18s rRNA tran-Pharmingen #18161D) and as detection antibody biotin anti-mouse
scripts, 18s Competimers (Ambion) were added at a primer:compet-IL-2 (2 
g/ml diluted in blocking buffer: PBS/2% BSA/0.05% Tween
imer ratio of 1:9. PCR was performed on an Eppendorf Mastercycler20; Pharmingen #18172D). Visualization at 405 nm was with Neutra-
using a hot start of 4 min at 94C, then 25 cycles of 30 s at 94C,vidin-AP (0.1 
g/ml in blocking buffer) and PNPP substrate solution
1.5 min at 72C, and 1 min at 55C, followed by a 7 min extension(Pierce). Experimental samples were compared with values from a
at 72C, which yielded PCR products within a linear range. PCRstandard curve, using known amounts of rIL-2 (R&D Systems).
products were separated on a 6% denaturing acrylamide gel, andAntiserum blocking studies were performed as described above,
HERV-K18 read-through transcripts were quantified by Phos-except that APC were preincubated for 30 min at 37C with rabbit
phorimaging (Molecular Dynamics). Induction was measured afteranti-Env peptide 116–130 antiserum, diluted 1:100 or 1:200 in me-
normalization against the 18s rRNA product.dium, or preimmune serum diluted 1:100 in medium. The APC/re-
sponder ratio was 2:1, with 2  104 THy per well. Plates were frozen
after 24 hr, and thawed supernatants were tested for mIL-2 by ELISA T Cell Proliferation Assays
PBMC were obtained from healthy adult volunteers, plated overnightas described above.
MHC class II blocking studies were performed as described above, at 37C in 10% FCS/complete RPMI media to allow monocytes to
adhere, and then used as a source of T cells. In all cases, autologousexcept that APC were preincubated for 30 min at 37C with anti-
HLA.DR, anti-I-A, anti-I-E, or anti-H-2D antibodies at 50 or 5 
g/ml. T cells were plated with B95-8 LCL. A20 transfected with HERV-K18.1
env or pCDLI, B95-8 LCL, or B95-8 marmoset cells were treatedBlocking was obtained with anti-HLA.DR at 50 
g/ml and with anti-I-E
at 5 
g/ml, whereas no blocking was seen with anti-I-A or H-2D at overnight with PMA (10 ng/ml) and then with mitomycin C (0.1 mg/
ml) for 1 hr and washed extensively with PBS, as described in theeither concentration. The APC/responder ratio was 1:1 with 2  104
Thy per well. Plates were frozen after 24 hr, and thawed supernatants THy assays. APC and T cells were resuspended at APC/responder
ratios of 1:1, 1:3, or 1:10, always using 105 T cells per well in quadru-were tested for mIL-2 by ELISA as described above.
LPS B cells were prepared by adding lipopolysaccharide from plicate using 96-well, round-bottom plates. After 48 hr at 37C, cells
were pulsed with [3H]thymidine (1 
Ci/well) for 12–16 hr and har-Salmonella typhimurium (50 
g/ml) (Sigma) to B cells purified from
the peripheral blood of three healthy adult donors. B cells were vested and counted for [3H] incorporation.
Antiserum blocking studies were performed identically; however,prepared by negative selection using the StemSep Antibody Cock-
tail for enrichment of human B cells (Stem Cell Technologies Inc., prior to addition of T cells, APC were preincubated for 30 min at
37C with anti-HERV-K18 Env peptide 116-130 antiserum, dilutedVancouver, Canada), according to manufacturer’s protocol. Non-B
lineage cells were removed with StemSepTM magnetic colloid, using 1:100 or 1:200 in medium, or preimmune serum diluted 1:100 in
medium.a 5 Tesla magnet. The resulting population of enriched B cells for
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